Your browser is no longer supported. Please, upgrade your browser.
XOMA XOMA Corporation daily Stock Chart
XOMA Corporation
Index- P/E2.61 EPS (ttm)8.86 Insider Own0.40% Shs Outstand8.57M Perf Week-1.49%
Market Cap198.22M Forward P/E- EPS next Y-0.64 Insider Trans-50.52% Shs Float7.75M Perf Month8.59%
Income69.90M PEG0.14 EPS next Q-0.20 Inst Own47.50% Short Float11.68% Perf Quarter2.16%
Sales52.90M P/S3.75 EPS this Y181.20% Inst Trans2.16% Short Ratio7.48 Perf Half Y-26.71%
Book/sh0.68 P/B34.01 EPS next Y33.30% ROA- Target Price41.00 Perf Year224.40%
Cash/sh- P/C- EPS next 5Y19.00% ROE- 52W Range6.86 - 37.25 Perf YTD-35.03%
Dividend- P/FCF- EPS past 5Y18.40% ROI326.10% 52W High-37.91% Beta2.62
Dividend %- Quick Ratio7.30 Sales past 5Y9.30% Gross Margin- 52W Low237.17% ATR0.84
Employees12 Current Ratio7.30 Sales Q/Q66.70% Oper. Margin- RSI (14)53.49 Volatility2.62% 4.28%
OptionableNo Debt/Eq0.00 EPS Q/Q80.50% Profit Margin- Rel Volume0.48 Prev Close23.02
ShortableYes LT Debt/Eq2.61 EarningsAug 08 BMO Payout- Avg Volume121.05K Price23.13
Recom2.00 SMA204.82% SMA501.46% SMA200-10.06% Volume58,335 Change0.48%
Jan-18-18Reiterated H.C. Wainwright Buy $38 → $49
Oct-17-17Resumed H.C. Wainwright Buy $38
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Mar-11-16Reiterated Wedbush Outperform $6 → $3
Jul-23-15Downgrade Jefferies Buy → Hold
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-22-15Downgrade Ladenburg Thalmann Buy → Neutral
Oct-10-14Resumed ROTH Capital Buy $9
Apr-29-14Upgrade MLV & Co Hold → Buy $7
Mar-11-14Downgrade MLV & Co Buy → Hold $8 → $7
Mar-05-14Reiterated Ladenburg Thalmann Buy $6.50 → $10
Oct-31-13Reiterated MLV & Co Buy $7.50 → $8
May-09-13Reiterated Ladenburg Thalmann Buy $5 → $6
May-14-12Initiated Cowen & Co Outperform
Mar-31-11Reiterated MLV Capital Buy $12 → $10
Mar-23-11Reiterated RBC Capital Mkts Outperform $8 → $6
Jan-06-11Reiterated Ladenburg Thalmann Buy $12 → $16
Jan-04-11Reiterated Wedbush Outperform $12 → $16
Jun-26-18 07:00AM  XOMA Added to the Russell 2000® and Russell 3000® Indexes GlobeNewswire
May-15-18 07:00AM  XOMA to Present at the UBS Global Healthcare Conference GlobeNewswire
May-09-18 06:11PM  Xoma: 1Q Earnings Snapshot Associated Press
04:05PM  XOMA Reports First Quarter 2018 Financial Results GlobeNewswire
May-08-18 07:00AM  XOMA Announces $20 Million Credit Facility with Silicon Valley Bank to Advance Royalty-Aggregator Business Model GlobeNewswire
May-02-18 07:30AM  New Research: Key Drivers of Growth for HTG Molecular Diagnostics, Impinj, XOMA, Stock Yards, TriCo Bancshares, and Alleghany Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Apr-03-18 07:00AM  XOMA to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire +5.89%
Mar-20-18 07:35AM  Investor Expectations to Drive Momentum within Key Energy Services, XOMA, Goldman Sachs BDC, Echo Global Logistics, Ellington Residential Mortgage REIT, and Phibro Animal Health Discovering Underlying Factors of Influence GlobeNewswire
Mar-07-18 05:46PM  Xoma reports 4Q loss Associated Press +7.78%
04:05PM  XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update GlobeNewswire
Mar-05-18 07:00AM  XOMA to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Feb-19-18 10:04AM  AbbVie Presents New Data on Upadacitinib for Crohn's Disease Zacks
Feb-16-18 09:56AM  FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review Zacks
Feb-14-18 05:48PM  AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda Zacks
Feb-08-18 11:26AM  Theravance, J&J Ink Deal for Inflammatory Intestinal Drug Zacks
09:49AM  Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down Zacks
Feb-06-18 10:00AM  Pfizer Files for Xtandi in Early Stage Prostate Cancer Zacks
Feb-02-18 10:00AM  Puma, CANbridge Team Up to Commercialize Nerlynx in China Zacks
09:30AM  Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review Zacks
Jan-31-18 09:17AM  Puma & Medison Team Up to Commercialize Nerlynx in Israel Zacks
Jan-30-18 11:14AM  Theravance's NDA for COPD Candidate Gets FDA Acceptance Zacks
Jan-29-18 10:22AM  Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion Zacks
Jan-26-18 03:54PM  East Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugs American City Business Journals
Jan-25-18 10:30AM  Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y Zacks
10:29AM  Shire Gets FDA Nod for Cinryze Tech Transfer to New Site Zacks
Jan-24-18 03:22PM  EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down Zacks
Jan-23-18 11:30AM  3 Pharma and Biotech Stocks to Watch Out for in 2018 InvestorPlace
10:45AM  Anthera's Sollpura Strong on Positive Futility in Phase III Zacks
09:42AM  Regeneron's Dupixent Receives MHLW Nod for Label Expansion Zacks
Jan-22-18 10:22AM  Bristol-Myers (BMY) Reports Data from CheckMate-142 Study Zacks
08:43AM  Acorda Therapeutics (ACOR) Jumps: Stock Rises 8.8% Zacks
Jan-17-18 09:36AM  Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It? Zacks
07:35AM  Recent Analysis Shows XOMA, Washington Real Estate Investment Trust, TransMontaigne Partners, Triumph, Hemispherx BioPharma, and Virtus Investment Partners Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jan-15-18 08:15AM  3 Pharma and Biotech Stocks to Watch Out for in 2018 Zacks
Jan-12-18 12:46PM  Aradigm's Bronchiectasis Candidate Has Negative FDA Vote Zacks
10:05AM  Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock? Zacks
Jan-11-18 09:46AM  Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU Zacks
08:01AM  Why is Novo Nordisk Stock Up More Than 50% in Past Year? Zacks
Jan-10-18 09:00AM  Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up Zacks
Jan-09-18 04:35PM  Acorda's Shares Down on Disappointing Ampyra View for 2018 Zacks
09:58AM  Novo Nordisk Confirms Bid for Ablynx But Faces Rejection Zacks
Jan-08-18 03:00PM  It was a banner year for stocks, but not everyone shared in the wealth. American City Business Journals
08:49AM  The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines Zacks
07:00AM  XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel GlobeNewswire
Jan-05-18 04:25PM  4 Biotech Stocks to Watch in the New Year Zacks
09:47AM  Emergent Starts Phase II Study on Anti-influenza Candidate Zacks
Jan-04-18 09:58AM  United Therapeutics (UTHR) Collaborates With Corsair Pharma Zacks -5.63%
09:53AM  Pfizer (PFE) Collaborates With Sangamo for Gene Therapy Zacks
Jan-03-18 01:40PM  Thermo Fisher Buys Phenom-World, Aids Analytical Instruments Zacks
09:41AM  Inovio Amends Chinese Deal for Immunotherapy, Shares Up Zacks
06:34AM  3 Best Healthcare Stocks of 2017 Motley Fool
03:04AM  Anika Therapeutics Receives FDA Nod for Bone Repair Therapy Zacks
Jan-02-18 09:09AM  PetMed Rides on Solid Reorders & New Orders Amid Competition Zacks
Dec-28-17 08:07AM  5 of the Best-Performing Biotech Stocks of 2017 Zacks
Dec-27-17 12:05PM  ETFs with exposure to XOMA Corp. : December 27, 2017 Capital Cube
Dec-20-17 03:44PM  3 Buy-Ranked Biotech Stocks That Soared in 2017 Zacks
02:21PM  Pfizer's Leukemia Drug Gets FDA Nod in First-Line Setting Zacks
07:43AM  Biogen, Ionis Ink Deal for Spinal Muscular Atrophy Therapies Zacks
Dec-19-17 10:30AM  Pfizer Hikes Dividend, Announces $10B Share Buyback Plan Zacks
07:30AM  Free Post Earnings Research Report: XOMAs Revenue Grew 5597.6% ACCESSWIRE
Dec-18-17 08:23AM  Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran Zacks
Dec-17-17 09:09AM  The 3 Best Biotech Stocks of 2017 Motley Fool
Dec-11-17 02:17PM  ETFs with exposure to XOMA Corp. : December 11, 2017 Capital Cube
07:01AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating XOMA Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Dec-08-17 08:10AM  Todays Research Reports on Stocks to Watch: Halozyme Therapeutics and Xoma Corporation ACCESSWIRE
Dec-07-17 08:35AM  XOMA Announces Exclusive License Agreement for XOMA 358 with Rezolute, Inc. GlobeNewswire +13.39%
08:30AM  AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc. GlobeNewswire
Dec-01-17 05:28PM  4 Biotech Stocks to Better Your Financial Health This Winter Zacks
Nov-30-17 02:40PM  ETFs with exposure to XOMA Corp. : November 30, 2017 Capital Cube +10.70%
Nov-29-17 08:43AM  XOMA Corp. :XOMA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube -6.58%
Nov-10-17 05:14PM  Xoma: A Lower Risk Way Of Investing In Biotech Forbes +6.36%
Nov-06-17 05:28PM  Xoma beats 3Q profit forecasts Associated Press
04:05PM  XOMA Reports Third Quarter 2017 Financial Results GlobeNewswire
Oct-29-17 11:41AM  3 Biotech Stocks That Turned $1,000 Into More Than $5,000 This Year Motley Fool
Oct-04-17 09:15AM  XOMA Announces Multiple New License Agreements for Proprietary Phage Display Libraries GlobeNewswire
Sep-19-17 07:00AM  XOMA to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-11-17 07:00AM  XOMA Earns $3 Million Milestone Payment from its License Agreement with Nanotherapeutics GlobeNewswire
Sep-07-17 02:17PM  ETFs with exposure to XOMA Corp. : September 7, 2017 Capital Cube +12.60%
Sep-06-17 08:10AM  Today's Research Reports on Stocks to Watch: Insmed Inc. and XOMA Corporation ACCESSWIRE
07:20AM  [$$] Novartis Deal Could Send Xoma Stock to $19
07:00AM  XOMA to Present at the Rodman and Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-28-17 08:20AM  Today's Research Reports on Stocks to Watch: Adamas Pharmaceuticals and XOMA Corporation ACCESSWIRE
Aug-25-17 05:56PM  ETFs with exposure to XOMA Corp. : August 25, 2017 Capital Cube +24.30%
07:00AM  XOMA Announces Transformational License Agreements for Gevokizumab and its IL-1 Beta Intellectual Property Portfolio GlobeNewswire
Aug-16-17 10:01AM  XOMA Corp. :XOMA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 Capital Cube
Aug-09-17 04:30PM  XOMA to Present New Growth Strategy at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-08-17 04:30PM  XOMA Reports Second Quarter 2017 Financial Results GlobeNewswire
May-18-17 07:00AM  XOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical Development GlobeNewswire
May-15-17 04:05PM  XOMA to Present New Strategic Initiatives at the UBS Global Healthcare Conference GlobeNewswire
May-09-17 06:32PM  Xoma reports 1Q loss Associated Press
04:05PM  XOMA Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-25-17 07:30AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and XOMA Accesswire
Apr-24-17 07:00AM  XOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition GlobeNewswire -8.02%
Apr-21-17 05:42AM  XOMA (XOMA) Shares March Higher, Can It Continue? Zacks
Apr-18-17 07:00AM  XOMA Presents Positive Data from PTH1R Monoclonal Antibody Program GlobeNewswire +14.00%
Mar-28-17 07:00AM  XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-27-17 05:02PM  XOMA CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfe +5.62%
Mar-23-17 09:30AM  Idera Pharmaceuticals and XOMA Find Paths to Financial Growth Accesswire +8.19%
07:00AM  XOMA Announces Four Presentations at the 2017 ENDO Meeting GlobeNewswire
Mar-22-17 01:04PM  XOMA CORP Financials +12.99%
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and other preclinical product candidates, such as interleukin 2, a therapy for metastatic melanoma and renal cell carcinoma, as well as anti-parathyroid receptor to address unmet medical needs. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration and licensing agreements with Novartis AG; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BURNS THOMAS M.SVP, Finance & CFOApr 27Option Exercise5.502,65514,6039,210Apr 27 05:44 PM
Neal James RCEOApr 27Option Exercise5.5015,65586,10331,988Apr 27 05:44 PM
BURNS THOMAS M.SVP, Finance & CFOApr 27Sale24.772,65565,7576,555Apr 27 05:44 PM
Neal James RCEOApr 27Sale24.4215,655382,23616,333Apr 27 05:44 PM
BURNS THOMAS M.SVP, Finance & CFOApr 26Option Exercise5.508,34545,89814,900Apr 27 05:44 PM
Neal James RCEOApr 26Option Exercise5.508,34545,89824,678Apr 27 05:44 PM
Neal James RCEOApr 26Sale24.698,345206,05016,333Apr 27 05:44 PM
BURNS THOMAS M.SVP, Finance & CFOApr 26Sale24.698,345206,0506,555Apr 27 05:44 PM
Neal James RCEONov 15Option Exercise4.0326,145105,36442,478Nov 15 08:03 PM
BURNS THOMAS M.SVP, Finance & CFONov 15Option Exercise4.038,39233,82014,947Nov 15 08:03 PM
BURNS THOMAS M.SVP, Finance & CFONov 15Sale27.058,392226,9786,555Nov 15 08:03 PM
Neal James RCEONov 15Sale27.0326,145706,76616,333Nov 15 08:03 PM
Neal James RCEONov 14Option Exercise4.038,58334,58924,916Nov 15 08:03 PM
BURNS THOMAS M.SVP, Finance & CFONov 14Option Exercise4.036,84727,59313,402Nov 15 08:03 PM
BURNS THOMAS M.SVP, Finance & CFONov 14Sale28.346,847194,0536,555Nov 15 08:03 PM
Neal James RCEONov 14Sale28.408,583243,74716,333Nov 15 08:03 PM
Neal James RCEONov 13Option Exercise4.0311,56846,61927,901Nov 15 08:03 PM
BURNS THOMAS M.SVP, Finance & CFONov 13Option Exercise4.036,98328,14113,538Nov 15 08:03 PM
BURNS THOMAS M.SVP, Finance & CFONov 13Sale30.996,983216,4196,555Nov 15 08:03 PM
Neal James RCEONov 13Sale30.8311,568356,67416,333Nov 15 08:03 PM